NEW YORK (360Dx) – TearLab will pursue initial US Food and Drug Administration clearance of a test card measuring a single inflammatory biomarker, MMP-9, in combination with the firm’s FDA-cleared osmolarity test, instead of two biomarkers plus osmolarity, as originally planned. The timing of the filing for FDA clearance is not expected to change, TearLab said, adding it still anticipates filing its FDA submission by the end of 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.